---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-080022"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2024-07-16T23:59:59+00:00"
generated_at: "2026-05-31T20:31:23.165627+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BioXcel reports preliminary Q2 2024 IGALMI net revenue of $1.1M, up 90% QoQ

## Summary
- Preliminary Q2 2024 net revenue from IGALMI approximately $1.1M, up 90% from Q1 2024 and 141% from Q2 2023.
- Growth driven by increased contracting with psychiatric clinics and behavioral health facilities via small commercial team.
- CEO cites potential for at-home expansion if BXCL501 approved, targeting estimated 23M annual agitation episodes.
- Full Q2 2024 financial results and business update to be discussed on a future earnings call (date TBD).

## SEC filing metadata
- accession: 0001104659-24-080022
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2024-07-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465924080022/0001104659-24-080022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465924080022/tm2419377d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-080022
- JSON: https://secwatch.observer/filing/0001104659-24-080022.json
- Plain text: https://secwatch.observer/filing/0001104659-24-080022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.